TriSalus Life Sciences, Inc. Annual Report - A Year in Review

Curious about TriSalus Life Sciences, Inc.'s performance this past year? This summary cuts through the financial jargon to give you a clear, straightforward look at their operations and financial health for the fiscal year ending December 31, 2023. Understand their progress, challenges, and what it means for potential investors.

Business Overview

TriSalus Life Sciences, Inc. (Nasdaq: TLSI) is a clinical-stage oncology company dedicated to developing innovative treatments for liver and pancreatic cancers. Their strategy centers on two key pillars: the Pressure-Enabled Drug Delivery™ (PEDD™) platform and their leading therapeutic candidate, SD-101. The PEDD platform aims to improve drug distribution within solid tumors by using pressure, overcoming a common challenge in cancer therapy. SD-101, an investigational Toll-like Receptor 9 (TLR9) agonist, is designed to activate the immune system directly within the tumor environment.

Throughout 2023, TriSalus primarily focused on advancing its clinical programs, meaning the company is still in the development phase and does not yet generate significant product revenue. As a "smaller reporting company" and a "non-accelerated filer" with the SEC, TriSalus has different, often less extensive, reporting requirements than larger companies. This status reflects their current market capitalization and revenue, indicating an earlier-stage company with potentially higher growth opportunities but also higher inherent risks. As of June 30, 2024, the total value of their publicly traded stock was approximately $111.5 million, with shares trading around $5.45. The company also has warrants (Nasdaq: TLSIW) that allow holders to buy stock later at $11.50 per share. If exercised, these warrants could dilute the ownership of existing shareholders.

Financial Performance

As a clinical-stage company, TriSalus reported minimal revenue of approximately $1.2 million for 2023, primarily from grants and collaboration agreements. This marks a slight increase from $0.8 million in 2022. The company incurred a net loss of $65.8 million in 2023, widening from a net loss of $58.1 million in 2022. This increased loss largely reflects their growing investment in research and development (R&D) as clinical trials progressed.

• Research & Development (R&D) expenses surged to $45.5 million in 2023, up from $38.9 million in 2022. This increase reflects the costs associated with their ongoing Phase 1/2 clinical trials for SD-101 in liver and pancreatic cancers.
• General and Administrative (G&A) expenses totaled $18.3 million in 2023, compared to $16.5 million in 2022. These costs increased due to expenses associated with operating as a public company and higher personnel costs.

Management's Discussion and Analysis Highlights

Achievements:

• Clinical Progress: TriSalus successfully completed enrollment for the dose-escalation phase of its Phase 1/2 study of SD-101 in patients with uveal melanoma with liver metastases. The company reported promising initial safety and efficacy signals. They also initiated the expansion cohort for their pancreatic cancer study.
• FDA Designations: The FDA granted Orphan Drug Designation to SD-101 for the treatment of pancreatic cancer. This designation could provide market exclusivity and tax credits.
• Intellectual Property: TriSalus strengthened its patent portfolio related to the PEDD platform and SD-101, securing key patents in major markets.

Challenges:

• Cash Burn: Significant R&D spending led to substantial cash consumption, requiring careful management of capital resources.
• Clinical Trial Delays: The company experienced minor delays at certain clinical trial sites due to staffing challenges and regulatory approvals, slightly impacting timelines.
• Competitive Landscape: The oncology sector remains highly competitive, with numerous companies developing therapies for similar indications, posing a challenge for market differentiation.

Financial Health

As of December 31, 2023, TriSalus reported cash and cash equivalents of $45.2 million, a decrease from $85.7 million at the end of 2022. This cash position is crucial for funding ongoing operations and clinical trials. Based on their current spending rate, management estimates this cash will fund operations into the third quarter of 2024. The company carries minimal long-term debt, primarily consisting of lease liabilities. However, TriSalus will likely need to raise additional capital through equity offerings or strategic partnerships to fund operations beyond mid-2024 and advance its clinical programs to later stages.

Future Outlook

TriSalus's strategy focuses on advancing SD-101 through clinical development, leveraging its PEDD platform to enhance drug delivery, and exploring new indications. Key milestones for 2024 include:

• Reporting additional data from their Phase 1/2 studies for SD-101 in liver and pancreatic cancers.
• Initiating a pivotal Phase 3 study for a lead indication, pending regulatory feedback and financing.
• Exploring potential strategic collaborations to accelerate development and commercialization.
• Continuing to optimize the PEDD platform for broader application.

Competitive Position

The oncology market, particularly for liver and pancreatic cancers, is highly competitive and rapidly evolving. TriSalus faces competition from large pharmaceutical companies, other biotechnology firms, and academic institutions developing or marketing therapies for similar indications. Key competitive factors include the efficacy, safety, and tolerability of product candidates, the speed and cost of development, intellectual property protection, manufacturing capabilities, marketing and sales capabilities, and market access.

TriSalus aims to differentiate itself through its unique Pressure-Enabled Drug Delivery™ (PEDD™) platform, designed to improve drug distribution in solid tumors, and its novel therapeutic candidate, SD-101, a TLR9 agonist intended to stimulate an immune response. The company believes this combination of targeted drug delivery and a novel immunotherapeutic approach may offer a competitive advantage in treating difficult-to-access tumors. However, competitors may develop more effective or less expensive treatments, or bring products to market faster, which could significantly impact TriSalus's potential market share and commercial success.

Risk Factors

Investing in TriSalus carries significant risks, typical for a clinical-stage biotech company:

• Clinical Trial Success: The success of SD-101 depends heavily on positive results from ongoing and future clinical trials, which are inherently uncertain. Failure to achieve primary endpoints could severely impact the company's value.
• Regulatory Approval: Even with positive clinical data, there is no guarantee of FDA or other regulatory approvals for their product candidates.
• Funding Needs: The company will require substantial additional capital to complete clinical development and commercialize any approved products. Failure to secure this funding could lead to delays or cessation of development.
• Competition: The oncology market is crowded. Competitors may develop more effective or less expensive treatments, or bring products to market faster.
• Intellectual Property: Protecting their patents and proprietary technology is crucial. Any challenges to their intellectual property could undermine their competitive advantage.
• Market Acceptance: Even if approved, there is no guarantee of widespread market acceptance by physicians and patients.

TriSalus represents a promising but high-risk investment, with its future tied to the successful development and commercialization of its innovative oncology treatments.